This article explains, in educational terms, drug-eluting stent — how the technology works and where it fits. The specific combination of wires, balloons, atherectomy, and stents is determined by the interventional cardiologist based on lesion complexity, calcification, and overall clinical picture. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Coronary Artery Disease and Percutaneous Coronary Intervention
Contemporary practice relies heavily on drug-eluting stents, which release an antiproliferative agent to limit the tissue overgrowth that can cause restenosis. The specific combination of wires, balloons, atherectomy, and stents is determined by the interventional cardiologist based on lesion complexity, calcification, and overall clinical picture. During PCI a lesion is usually crossed with a guidewire, prepared with a balloon, and in most cases scaffolded with a stent that holds the vessel open.
Drug-Eluting Stent (DES) Technology
A drug-eluting stent combines a thin metallic scaffold with a polymer coating that releases an antiproliferative drug into the vessel wall over time. The eluted drug is intended to suppress the neointimal hyperplasia that drives in-stent restenosis after a bare scaffold is placed. INVAMED's ATLAS Drug Eluting Coronary Stent System uses a cobalt-chromium L605 platform with 60 micrometer struts and a sirolimus coating dosed at 1 microgram per square millimeter with sustained controlled release. According to INVAMED, clinical data for the ATLAS DES show target lesion revascularization rates below 5% at 12 months, a figure that reflects studied performance rather than an individual guarantee.
Design and Technical Notes
INVAMED groups its coronary portfolio around the sequence of a PCI case, offering access, lesion preparation, drug delivery, scaffolding, and closure devices. Guide extension catheters can provide the backup support needed to deliver devices in tortuous or distal anatomy. Thin-strut cobalt-chromium platforms are intended to balance deliverability with radial support in a range of vessel sizes.
Key Considerations
- Guide extension catheters can provide the backup support needed to deliver devices in tortuous or distal anatomy.
- Dual antiplatelet therapy duration is individualized to the clinical presentation and the patient's bleeding risk.
- All INVAMED coronary devices are intended for use by trained interventional cardiologists under fluoroscopic guidance and per the IFU.
Frequently Asked Questions
What is the reported restenosis performance of the ATLAS DES?
INVAMED reports clinical data showing target lesion revascularization rates below 5% at 12 months; this reflects studied performance and is not an individual guarantee.
Who decides between PCI and bypass surgery?
That decision is made by a clinical heart team based on coronary anatomy and individual factors; this article is educational and not medical advice.
What is the INVAMED drug-eluting stent called?
INVAMED's drug-eluting coronary stent is the ATLAS Drug Eluting Coronary Stent System, built on a cobalt-chromium L605 platform with a sirolimus coating.
About INVAMED
INVAMED operates a dedicated R&D center (INVAcenter) focused on minimally invasive device development. INVAMED states it maintains a growing portfolio of international patents across its device range.
Clinical and Technical Context
INVAMED's Extender Drug Eluting PTCA Balloon Catheter carries a paclitaxel coating for this local drug-delivery role. INVAMED's ATLAS Drug Eluting Coronary Stent System uses a cobalt-chromium L605 platform with 60 micrometer struts and a sirolimus coating dosed at 1 microgram per square millimeter with sustained controlled release. Because a drug-coated balloon leaves nothing behind, it is one option a clinician may weigh when a metallic implant is less desirable. Wire selection is a hands-on decision made by the operator according to lesion morphology and crossing strategy. INVAMED's ATLAS system elutes sirolimus at 1 microgram per square millimeter with a sustained controlled-release profile designed to cover the early healing window. Whether a closure device is used, and which type, is determined by access site, sheath size, and clinician preference. INVAMED's Inwire PTCA Guidewire is offered for coronary wiring within the interventional line, alongside CTO and workhorse options. Dual antiplatelet therapy duration is individualized to the clinical presentation and the patient's bleeding risk.
Related on INVAMED
- Coronary Artery Disease & Cardiac Interventions — product category
- Comparing Durable-polymer DES and Biodegradable-polymer DES
- Sourcing Coronary Artery Disease & Cardiac Interventions Devices: A Manufacturer and Procurement Guide
- Arterial Access Closure: How It Works and Why It Matters
Important Disclaimer
This article is intended for general educational and technical information about medical device technologies. It is not medical advice, a diagnosis, or a treatment recommendation, and it does not replace consultation with a qualified healthcare professional. Any decision about diagnosis or treatment should be made by a licensed clinician based on an individual assessment. INVAMED devices are intended for use by trained healthcare professionals in accordance with the applicable Instructions for Use (IFU) and local regulatory approvals. Product availability and indications vary by country.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.